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O objetivo principal desta dissertação é desenvolver modelos para pro-
por moléculas de interesse que podem se tornar em princípios ativos
no tratamento da brose quística. Neste projeto apresenta-se uma
abordagem in silico para a seleção de moléculas que possivelmente
têm capacidades terapêuticas em relação à brose quística. Este pro-
cesso é efetuado computacionalmente com a utilização de ferramentas
de prospeção de dados e os objetivos primordiais deste processo são
a identicação e seleção de moléculas que podem ajudar no combate
à doença para posterior teste em laboratório. Para este efeito foram
desenvolvidos previsões para a capacidade terapêutica das moléculas
em dois espaços: i) espaço vetorial; ii) espaço métrico. No espaço
vetorial as previsões foram realizadas tendo em conta os descritores
moleculares das moléculas, com recurso ao método estatístico e com-
putacional random forest. As moléculas foram também representadas
num espaço métrico construído com a dissemelhança molecular entre
as mesmas, onde ocorreu uma redução de dimensões tornando pos-
sível a representação das instâncias num plano bidimensional - este
espaço métrico foi subsequentemente analisado por uma ferramenta
estatística denominada kriging.
Para comprovar os métodos escolhidos, usaram-se dois conjuntos de
dados; potenciadores e ativadores de anoctaminas (moléculas de pos-
sível interesse para o tratamento da brose quística) e corretores
da proteína causadora da brose quística (CFTR - Cystic brosis
transmembrane conductance regulator). No âmbito desta dissertação,
foram identicadas 10 moléculas provenientes do estudo com poten-
ciadores de anoctaminas e 18 moléculas provenientes do estudo com
corretores da CFTR, para serem testadas em laboratório.
Adicionalmente, foram recolhidos dados de repositórios de informação
biológica para validar os métodos utilizados. Este passo adicional
permite concluir que algumas das moléculas escolhidas têm ligações
diretas e indiretas à brose quística, dando credibilidade ao método
desenvolvido.
É importante referir que a forma como este projeto foi desenvolvido
permite a utilização de diferentes conjuntos de dados de ligandos para
proteínas alvo, o que torna este método exível e adaptável à doença
que seja objeto de estudo.
Palavras Chave: Chemoinformatics, Aprendizagem Automática,
Fibrose Quística, Design de Medicamentos In Silico
Abstract
The main goal of this dissertation is to develop models in order to
identify and propose lead chemical molecules that can possibly become
principal actives against the cystic brosis disease.
In this project it is presented an in silico approach to perform a molec-
ular screening on possible therapeutic candidates for the cystic bro-
sis disease. This process is done computationally with data mining
tools and the main objectives are the identication and selection of
molecules to further testing in the laboratory. To achieve this goal the
data mining exercise was developed on two spaces: i) vectorial space,
ii) metric space. On the vectorial space, molecular descriptors were se-
lected to implement a random forest algorithm (a supervised machine
learning method) in order to realize forecasts on the molecule ability
to treat the disease. The studied molecules were also represented in
a metric space that was developed using molecular dissimilarity be-
tween all molecules. This dissimilarity values were modelled to t in
a 2 dimensional representation - In this metric space the statistical
tool chosen was kriging.
To prove the chosen methodology, two main datasets were used: A
dataset with Anoctamin activators or potentiators (molecules of inter-
est to treat the cystic brosis disease) and a dataset with correctors
of the protein which causes cystic brosis (CFTR - Cystic brosis
transmembrane conductance regulator). Based on these datasets, 10
and 18 molecules were selected respectively to be further tested in a
lab environment.
To conclude the work and validate the workow results, an additional
analysis was performed using selected information repositories. This
additional step has conrmed that some of the chosen molecules are
directly and indirectly related to cystic brosis, giving some credibility
to the proposed method.
Finally, the way this project was developed enables the use of dier-
ent datasets with ligands of the target proteins as input, making the
method exible and adaptable to any disease in study.
Keywords: Chemoinformatics, Machine Learning, Cystic Fibrosis,
In Silico Drug Design
Resumo Alargado
Atualmente existem diversas doenças para as quais se conhecem os
seus mecanismos biológicos, mas para as quais ainda não existe qual-
quer tipo de medicamento, ou os disponíveis não são sucientemente
ecazes. Nos últimos anos, o número de novas moléculas a chegar
ao mercado tem sido cada vez menor, como tal é necessário novas
abordagens para a descoberta e desenvolvimento de novos princípios
ativos. Além disso, todo o processo para criar um novo medicamento é
extremamente caro e demorado e a grande maioria dos compostos de-
senvolvidos nunca chegam a ser comercializados. Como tal, qualquer
hipótese de reduzir o tempo e o preço da investigação bem como de
aumentar as probabilidades de sucesso é importante para estudo. O
desenvolvimento computacional de medicamentos apresenta-se como
um método capaz de contribuir para a resolução destes problemas.
Comparativamente aos tradicionais métodos de descoberta e desen-
volvimento de medicamentos, o desenvolvimento computacional uti-
liza algoritmos, conhecimento biológico prévio e grandes quantidades
de informação para uma seleção rápida e precisa de moléculas para
posterior análise em laboratório. O desenvolvimento pode ser baseado
na estrutura do alvo ou no ligando.
O foco deste projeto foi a seleção de moléculas de interesse com a
utilização de uma abordagem baseada na estrutura do ligando, mais
especicamente, um modelo QSAR (da relação entre estrutura e ativi-
dade de forma quantitativa,) com uma pesquisa de moléculas uti-
lizando uma base de dados ZINC, que é constituída por todos os
compostos comercialmente disponíveis.
O caso de estudo escolhido para desenvolver a metodologia deste pro-
jeto foi a brose quística, uma doença genética recessiva das mais co-
muns. Embora atualmente já existam alguns medicamentos para esta
doença, estes não são considerados ecazes nem podem ser admin-
istrados em todos os pacientes. A CFTR (cystic brosis transmebrane
condutance regulator) é uma proteína que quando tem alguma mu-
tação e subsequente malformação, leva à manifestação desta doença.
A mutação mais frequente é a F508del, uma deleção no resíduo 508,
uma fenilalanina. É uma proteína canal cuja função é transportar
cloro, mais especicamente Cl− .
Para este método selecionou-se moléculas provenientes de dois con-
juntos de dados: i)moléculas potenciadoras ou ativadoras de anoc-
taminas e ii)moléculas corretoras da CFTR com a mutação F508del.
As anoctaminas são um grupo de proteínas também canal que trans-
portam Cl− ativadas por Ca2+ e que estão bem distribuídas em vários
tipos celulares. Estas características tornam as anoctaminas em alvos
interessantes para combater indiretamente a brose quística. Neste
grupo de dados estão presentes 10 moléculas corretores ou ativadores
de anoctaminas. No conjunto de dados com corretores da CFTR es-
tão presentes 109 moléculas que foram testadas em laboratório com
recurso à técnica de Western Blot.
O método de desenvolvimento de medicamentos computacional foi
construído numa plataforma chamada KNIME, que permite alojar
pequenos programas (em diferentes linguagens de programação) de
forma interligada, bem como já contém diversos nodos de interesse
estatístico e/ou biológico entre outros. Tendo em conta o objetivo
nal deste projeto - a seleção de moléculas de interesse para serem
posteriormente testadas em laboratório - este método foi assente em
dois ramos de trabalho, um que analisa os dados num espaço vetorial
e o segundo num espaço métrico. Os resultados de ambos foram con-
jugados para selecionar as moléculas a serem testadas posteriormente.
Mais detalhadamente, existiu uma seleção na base de dados ZINC por
moléculas semelhantes às iniciais ( tanimoto > 0.75 ) sendo que estas
foram posteriormente alvo de previsões relativamente à sua capaci-
dade terapêutica em relação à brose quística. Cada um dos ramos
recebeu as moléculas iniciais, os seus valores testados em laboratório
em relação à doença, bem como a estrutura das moléculas semelhantes
retiradas do ZINC. No ramo vetorial, as moléculas iniciais passaram
por um nodo do RDKIT que calculou os seus descritores moleculares.
Esta informação juntamente com os valores previamente obtidos em
laboratório, foram utilizados para treinar a random forest - método
estatístico e estocástico baseado na construção de uma oresta de ár-
vores de decisão. O modelo foi assim criado e utilizado para prever
os valores das moléculas selecionadas do ZINC. No ramo métrico, as
moléculas foram comparadas utilizando o NAMS, um programa que
utiliza a estrutura das moléculas, nomeadamente os átomos e as lig-
ações entre átomos, para comparação da semelhança molecular. Neste
programa, seleciona-se uma das cinco matrizes de substituição de áto-
mos disponíveis, permitindo a escolha de uma matriz mais ou menos
estrita a substituições. Com a semelhança molecular foi calculada a
distância entre compostos com -log(semelhança). A partir da matriz
de distâncias entre moléculas conrmou-se com a análise de compo-
nentes principais que era signicativo representar as moléculas em
duas dimensões. Foi também efetuada uma análise das coordenadas
principais para calcular as coordenadas das moléculas nesse espaço.
De forma a ser possível representar as moléculas semelhantes retiradas
do ZINC no mesmo plano, foi calculada uma matriz de transformação
com recurso à matriz de distâncias iniciais e à matriz das coordenadas
das moléculas iniciais. Foi então efetuado uma previsão dos valores
de melhoria da atividade das anoctaminas ou da CFTR (dependendo
do conjunto de dados) de cada molécula semelhante, com recurso a
uma técnica de geo-estatística, conhecida como kriging. Esta técnica
de geo-estatística baseia-se na interpolação espacial utilizando pontos
espaciais com valores já determinados para prever valores de outras
localizações.
Com as previsões resultantes de ambos os ramos de trabalho, foi con-
struído um gráco dos valores previstos, para auxiliar na seleção de
moléculas com mais interesse para posterior análise laboratorial.
No que diz respeito aos dados dos potenciadores e ativadores das anoc-
taminas, a comparação molecular com recurso ao NAMS indicou que
a correlação só existia nas matrizes mais estritas, o que signica que
substituições, mesmo que de átomos semelhantes, afetam muito a ca-
pacidade terapêutica da molécula. Neste conjunto de dados foram
selecionadas 10 moléculas : 8 com valores elevados nos dois ramos de
trabalho e 2 adicionais que apresentam um valor previsto elevado num
ramo e baixo no outro. Estas 2 moléculas com valores discordantes,
foram principalmente selecionadas para posteriormente se avaliar em
laboratório o ramo com a melhor previsão e identicar possíveis mel-
horias. Após a escolha destas moléculas foram recolhidos dados de
repositórios de informação biológica para validar os métodos utiliza-
dos. Com base nesta recolha de informação, foi possível concluir que
as moléculas selecionadas apresentam ligações possíveis às anoctam-
inas e a uma proteína canal com algumas características em comum
com as anoctaminas. A recolha de informação permitiu também saber
que uma das moléculas selecionadas foi já testada como molécula que
poderia atuar como chaperona, indicando que poderia corrigir mal-
formações em proteínas.
Não se efetuou validação do método utilizando os dados das anoctam-
inas umas vez que o seu número é demasiado reduzido. Quando se
efetuou a validação com o conjunto de dados de corretores da CFTR
encontrou-se valores incoerentes com a previsão adequada, o que após
revisão de todas as técnicas e algoritmos levou a uma análise detal-
hada dos dados. Estes revelaram-se como erros de etiquetagem das
moléculas, o que foi posteriormente corrigido com a utilização de sup-
port vector machine. Os dados corrigidos foram testados com recurso
a um estudo de atividade molecular sobre a CFTR, (retirado de um
repositório publico - Pubchem) e posteriormente utilizados então para
o processo de virtual screening.
Em relação aos dados de corretores da CFTR, foi possível observar
que as matrizes de substituição apresentaram correlação nas duas ma-
trizes mais estritas, bem como numa mais equilibrada. Com os resul-
tados obtidos após a combinação das previsões foi possível escolher
18 moléculas para posterior análise: 6 com valores elevados nos dois
ramos de trabalho e nas 3 matrizes, 4 com valores elevados nos dois
ramos e em 2 matrizes, 3 com um valor elevado no espaço vetorial
mas baixo no métrico, 3 com um valor elevado no espaço métrico e
baixo no vetorial e 2 com valores discordantes entre matrizes. Tam-
bém neste caso foram recolhidos dados de repositórios de informação
biológica conrmando que algumas moléculas tinham ligações à -
brose quística, especialmente as anoctaminas e histonas deacetilases
que já foram referidas em artigos cientícos como tendo inuência na
doença.
As informações encontradas nos repositórios parecem dar credibili-
dade a todo o processo apresentado nesta dissertação, no entanto
testes em laboratório são necessários para um maior entendimento
e até possível melhoria do método. Sugere-se que após obtidos os
resultados em laboratório, se faça outra iteração deste processo, de
forma a aumentar a sua capacidade de previsão. Para além disso,
como foram observadas diversas zonas de interesse no espaço métrico
onde não existiam moléculas, seria interessante desenhar moléculas
com as características necessárias para se localizarem nesses pontos,
e testar as mesmas quer no espaço vetorial quer em laboratório.
É importante referir que a forma como este projeto foi desenvolvido
permite a utilização de diferentes conjuntos de dados de ligandos para
proteínas alvo, o que torna este método exível e adaptável à doença
que seja objeto de estudo.
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The nitrogen in our DNA, the calcium in our teeth, the iron in our blood, the
carbon in our apple pies were made in the interiors of collapsing stars. We are
made of starstu.
Carl Sagan, Cosmos
Today it is already possible to understand how a big number of diseases
work in a biologically way, however, the information is scattered across dierent
databases while several work groups keep trying to solve the same issues around
the same diseases. Plus, the nancial landscape in the investigation sphere is not
always aligned with the current spending needs for each problem.
One may try to tackle some of these problems by using previous informa-
tion about biological targets stored across the aforementioned databases and a
computational methodology. The traditional drug design approach requires a
tremendous amount of money, time, as well as human resources to identify and
bring into the market a completely new drug (gure 1.1). This in combination
with the ever-increasing demand for new drugs, has called in recent times for more
ecient and cost-eective computational and automated drug design approaches.
Automated programs being fed by the vast amount of biological data currently
available predict how substances would react and require fewer investigators and
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less utilization of consumables at the lab (reagents or otherwise), resulting in
fewer resources (human and nancial) needed to reach the desired outputs.
Figure 1.1: Cost of dierent stages in drug investigation from 1970 to 2010. From
(DiMasi et al., 2016)
For the purposes of this dissertation, cystic brosis (CF) was chosen as the
target disease to be further studied and analysed. This disease causes a thick
mucus in the respiratory and digestive system, with several deadly complications,
mainly, diculty in breathing and bacterial infection in the lungs. It is also
common to have digestive problems like diculties in absorbing nutrients and
constipation (Boucher, 2007). The average life expectancy for CF patients is
about 37 years old, with lung or cardiorespiratory complications being the main
causes of death. Cystic brosis is one of the most common recessive genetic
diseases, aecting 1 in every 2500 newborns in Caucasian populations, (Zielenski
and Tsui, 1995) with dierent prevalences across countries and within human
populations. It is characterized by a misfolding of a channel protein called CFTR
(cystic brosis transmembrane conductance regulator,) which is a ABC (ATP-
binding cassette) transporter of chloride. The deletion of a phenylalanine at
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residue 508 (F508del) is the most common cause of CFTR misfolding (Wang
and Li, 2014b). More than 90% of cystic brosis patients carry at least one
copy of the CFTR gene with the F508del mutation, causing impaired exocytic
tracking (Cheng et al., 1990), and the retention of the malformed protein in the
endoplasmic reticulum, leading to its consequent degradation.
The drugs available by the end of 2016 are very expensive1, scarce, not very
eective and were only designed to work in specic patients groups (Cholon et al.,
2015). As such it becomes truly important to nd drugs that cure and/or coun-
teract the CF eects. To treat this disease there are two possible courses, the
correction of the protein responsible for the illness,(cystic brosis transmembrane
conductance regulator,) or potentiating another channel protein that transport
the same ions (like the anoctamins family) and therefore, counteract the poorly
functioning CFTR. It is very clear that allying the need for a new CF drug and
the feasibility of predicting chemical compounds reactions in an automated way is
compelling and most important, a necessary evolution that many patients expect.
1.2 Objectives
The main goal of this dissertation is to propose lead chemical molecules that can
possibly become principal actives against cystic brosis. Although all the follow-
ing work was developed for this disease, the methods used in this dissertation can
be applied for other diseases, depending only on the input dataset.
Hypothesis: Using datasets from cystic brosis drug response in combination
with machine learning methods, it is possible to predict the therapeutic
capacity of chemical compounds present in databases.
1DRG blog, While Kalydeco Sailed Through, Vertex's Orkambi Faces Strong Headwinds in




The main contributions of this work will be:
Contribution 1: Create a new computational model to predict therapeutic ca-
pability of each compound using metric and vectorial distances.
Contribution 2: Identify molecular features of interest.
Contribution 3: Select lead compounds to be tested in vitro.
In this dissertation, the drug design process will use dierent methods to
assert the capability of each compound, (retrieved from a database,) to become
a possible drug for cystic brosis. This method can support the decision process
around the selection of which molecules should be tested, reducing the human
and nancial resources, as well as the time needed for the drug design process.
1.4 Drug Discovery and Development
Drug discovery is considered the process from the start of the investigation of a
specic disease until the designed drugs are ready for in vitro and/or in vivo test-
ing. The development phase includes pre-clinical, clinical, approval and surveil-
lance steps.
The process of drug research has changed dramatically over the years. Ini-
tially, drugs were developed using traditional remedies from natural medicine
that were analysed using old-fashioned methods, in order to identify the respec-
tive active component, and subsequently transform it into a usable drug. Along
the years, techniques evolved and became more complex and capable, such as,
using cells to perform tests on molecules and natural extracts. Nowadays, drug
design techniques are far more complex involving several scientic elds such as
medicine, biotechnology, pharmacology, structural biology, computational chem-
istry and much more.
The entire drug discovery and development process - that starts with un-
derstanding the disease in study, and ends when a drug reaches the market -
includes several renements of the selected compounds, where the objective is to
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Figure 1.2: Representation of Drug research stages, incuding the continuated
selection of compounds. Adapted from Genome Research Limited
nd the cure and at the same time be relatively inclusive to not lose any impor-
tant compound in one of this renements (g 1.2). The complete process can be
described in 8 steps: First, it is necessary to understand the disease, this means
nd patient symptoms and possible targets, and proceed to isolate and test this
targets for their functions and relations with the disease in study (Anderson,
2003). After this, the target needs to be validated, with several tests being per-
formed to ensure the connection with the disease, their specic function as well
as their mechanism of biological control (for example binding partner molecules)
(Chen and Chen, 2008). Once the targets are found and validated, it is necessary
to nd compounds with the ability to interact with the drug target in a positive
way - lead identication (Kalyaanamoorthy and Chen, 2011). It is very important
to select several lead compounds to ensure a broader probability to identifying a
clinical candidate. After the identication, an analysis of the selected compounds
should be performed to nd important characteristics, evaluate their potency and
improve it. Some pharmacological or biological properties are required to be eval-
uated as well and can be done with the aid of computational biology. After this
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process, the selected compounds are synthesized into a drug and the preclinical
stages begin where in vitro and/or in vivo tests are performed on the synthesized
drug (and potential reformulations) to evaluate the toxicity and the potency of
the compounds. If the preclinical tests show positive and promising results, the
selected compounds move on to the clinical trials stage, where for the rst time,
humans are used to evaluate the eectiveness and safety of the drug. A clinical
trial is carried out to ascertain safety, side-eects, dosage, and ecacy and it is
divided into several phases as described in gure 1.2. The compound candidates
that passed the 2 previous phases are subjected to a nal evaluation from the
regional regulatory entity. This is the last barrier to get the required approval to
start marketing the drug. The regulatory entities who evaluate the drugs dier
from country to country and are very restrictive and demanding on this process
to ensure the safety of the population, as well as the eectiveness and the eco-
nomic impact of the drug. After a drug is approved, it continues under evaluation
during its lifetime. Even with the clinical trials, it is possible that the entire or a
portion of the population reacts dierently than predicted.
1.5 Computational Drug Design
Computational Assisted Drug Design (CADD) is the use of computational meth-
ods to facilitate the design and discovery of new therapeutic solutions and its
main objective is to help identify and select the most promising candidate drugs.
It is during the drug discovery process, where a signicant number of molecules
can be identied as candidate compounds, that CADD can intervene the most.
Using in silico testing, CADD can help on the selection of the molecules more
prone to have better results. Currently, there are two ways to design a drug using
the CADD process:
Structure-based drug design Using the 3D information about the biological
target, one can create molecules from scratch (de novo approach) or use
molecular databases for screening - virtual screening.
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Ligand-based drug design When the 3D information about the target pro-
tein is not available, it is possible to use a set of ligands to identify some
properties. This identication uses one of the following approaches:
- QSARs Quantitative structure-activity relationships models
- Pharmacophore based models that use functional groups and enforces
small changes in the molecules but with similar structures.
In this thesis, the approach chosen was a QSAR model because the provided
dataset was based on molecular information and structure of ligands to the target.
1.6 QSAR - Quantitative structureactivity rela-
tionship
With the ever growing number of chemical compounds available in databases, it
is necessary to nd robust and ecient ways to select interesting molecules with
the ability to become drugs (Tropsha, 2010). Quantative structure-activity rela-
tionship model is a ligand-based drug design, which creates a model from tested
chemical compounds, to perform virtual screening in order to predict character-
istics of new compounds.
This approach relies on a simple similarity principle: compounds with similar
structures are expected to have similar biological activities.
QSAR can be divided into metric and vector approaches: the metric approach
usually relies on some type of molecular comparison and a subsequently statistic
analysis like k-nearest neighbour (Paredes and Navarro, 2006); the vector ap-
proach uses data mining techniques such as support vector machines (Hasegawa
and Funatsu, 2010) over the calculated molecular descriptors.
1.7 Current Cystic brosis available treatments
Currently, the few drugs available (ivacaftor and lumacaftor) are not very eec-
tive, as they only target certain CFTR mutations (Cholon et al., 2015). Some-
times it is still necessary to perform a lung transplant, with the complications
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associated with that surgery being very considerable. Also, to avoid the prolifer-
ation of bacteria from one lung to another it is necessary the transplantation of
both lungs.
Ivacaftor is a potentiator and its main goal is to help the channel to transport
the chloride, targets the G551D substitution mutation - the CFTR can reach
the membrane but is not very competent on transporting chloride (only 4-5% of
cystic brosis patients have it).
Lumacaftor, as a corrector, doesn't have a medical use by itself since it only
corrects some of the protein misfolding ("chaperone-like" eect). When used in
combination with ivacaftor, it can help in the treatment of F508del mutation.
However, lumacaftor has a restrictive use and can only be applied in homozygous
patients with more than 12 years old. Orkambi (lumacaftor 200 mg and ivacaftor
125 mg) was rejected by the U.K.(in March 2016) and by Ireland (in June 2016)
national healthcare system due to lack of cost eectiveness 1.
1.7.1 The Anoctamins hypothesis
Anoctamins are a family of channel proteins that produce Ca2+ activated Cl−
currents. They are present in several tissues like endothelium, visceral smooth
muscle Cajal cells, heart, airways, alveoli and colon. This family of proteins does
not show any obvious homology to other ion channels(Kunzelmann et al., 2011).
Since they transport the same molecule and are present in several important tis-
sues, these channels are a possible way to counteract the eects of a dysfunctional
CFTR. Ano 1 is the most promising target candidate since it exists in dierent
cell types spread throughout the human body (Kunzelmann et al., 2011).
1DRG blog, While Kalydeco Sailed Through, Vertex's Orkambi Faces Strong Headwinds in




The rest of this dissertation is organized as:
2nd Chapter: State of the art with more detailed information about the tools
that will be used and also some contextualization to in silico drug design.
3rd Chapter: Description and explanation of the datasets origin.
4th Chapter: Overview of the entire workow.
5th Chapter: Presentation of the results.
6th Chapter: Discussion of the results and selection of molecules.
7th Chapter: Conclusions.
The appendices contain:
A - List of molecular descriptors used.
B - Workow images.




This project consisted in 3 main areas of activities across 21 months: Research
of state of art and available tools (4 months); workow development, testing,
improvement, and validation (14 months); and report (9 months).




"Knowledge has to be improved, challenged, and increased constantly, or it
vanishes."
Peter Drucker
Given the current cost to bring a new drug to the market (around US$2.5
billion (2013 dollars) as well as the 10-15 years needed to go through the entire
process (DiMasi et al., 2016) (Clark, 2008) it is necessary to develop tools that
ensure the investment is applied to the most promising molecules. The number
of new molecular entities (NMEs) is growing substantially each year but the
number of molecules that reach the market continues to diminish (Paul et al.,
2010). The adoption of CADD increases the probability of commercializing a
drug, since, compared with other methods (like high-throughput screening (HTS))
this rational drug design approach is based on knowledge instead of testing and
aims to understand the disease giving information about the ligands anity and
their mechanism (Lionta et al., 2014).
2.1 Computer assisted Drug Design
CADD is the development of drug design with the aid of computational methods.
As in (Martins et al., 2012), computational models can be a viable alternative
to high throughput screening, as computer power becomes more aordable and
more data available, complex and accurate models may be produced.
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Figure 2.1: Workow of LBDD and SBDD in computer-aided drug design. From
(Joy et al., 2015)
The amount of molecules with probability to become a drug is extensive,
making it impractical to test them all in vitro. In silico testing can help solve
this situation, as well to aid in decreasing the costs when compared to HTS.
This method can reduce the time needed for the initial steps of drug discovery
diminishing the time-to-market (Martins et al., 2012).
As previously described, computational drug design refers to the discovery
and optimization of drug candidates and can be divided into two categories (g-
ure 2.1): structure based (SBDD) and ligand based (LBDD) drug design.The
previous biological knowledge of either the target structure or ligands with bioac-
tivities is the determining factor in choosing which approach should be used.
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2.1.1 LBDD - Ligand based drug design
When the 3D structure of the target is not known it is possible to use several
active ligands of the target and make predictions about the structure of the target
(or of the ideal candidate molecule). Also, with the molecular structure of the
ligands, it is possible to make predictions of their chemical/molecular properties.
This type of design is based on the premise that similar structural compounds
will interact with the same target. As this approach relies on the similarity
between compounds, choosing the correct algorithm/formula to compare them is
a determinant step. LBDD techniques can be used even when the information
about the target and the ligand are scarce or nonexistent, by using the genetic
sequence of the target and assuming that similar receptors interact with similar
ligands (Klabunde et al., 2009). The most common methods are QSAR/QSPR
and Pharmacophore modelling.
2.1.1.1 QSAR/QSPR - Quantitative structure-activity/property re-
lationship
This method relies on the principle of similarity were molecules with similar
structure will be more prone to have similar bioactivities and the variation in
bioactivities is related with structural and/or molecular variations. Using a set of
ligands, statistical tools, and a machine learning method, the goal of this project
is to create an algorithm that can predict characteristics of new entities, using
only information about their structure. (Tropsha, 2010) has dened a generic
representation of a QSAR model as:
Pi = k(D1, D2, ..., Dn)
2.1.1.1
Where;
Pi - Characteristic of interest to predict;
k - Transformations to the data executed by the model;
D1, D2 and Dn - Molecules;
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QSAR modelling can be divided into two broader categories: i) regression,
where the variable to predict is continuous and ii) classication, where the algo-
rithm will predict in which class does one element belong.
There are several commercial and free software available, some with a black-
box approach. CoMFA (Comparative Molecular Field Analysis) uses a superim-
posed strategy to compare the molecular structure and make inferences about
their biological activities (Cramer et al., 1988). GOLPE, (Generating Optimal
Linear PLS Estimations) program obtains partial least squares estimations with
the best possible prediction (Baroni et al., 1993). ADAPT (Automated Data-
Analysis and Pattern Recognition Toolkit)1 is a commercial program that predicts
values using a training set and has several subsystems to receive the graphical
input of molecules, stored them in connection tables and create and evaluate
the substantial structure molecular descriptors available(Stuper and Jurs, 1976).
Regardless all the programs currently available, other statistical or data min-
ing software (not created specically for drug design) can be used, such as: R2,
MatLab3, SPSS4, KNIME5.
2.1.1.2 Pharmacophore modeling
Pharmacophore modeling uses compounds with a similar 3D structure on the
principal functional groups, and a wide range of structure and dierent atoms in
the other groups not considered as principal (Vuorinen and Schuster, 2015) there-
fore, selects the common chemical features that represent the ability of that set
of ligands to interact with the target. This type of modeling has two main steps:
i)represent the conformational exibility of the ligands and ii) nd the minimum
required common features, to develop the pharmacophore model (Yang, 2010).
There are several programs for this technique: the Ligand Scout is a very specic
1ADAPT http://research.chem.psu.edu/pcjgroup/adapt.html, last accessed on 14 August
2016
2R https://cran.r-project.org/, last accessed on 14 August 2016
3MatLab http://www.mathworks.com/products/matlab, last accessed on 14 August 2016
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program that uses only a set of six types of chemical features and volume con-
straints when searching in databases(Wolber and Langer, 2005); the Discovery
studio software suite1 has several tools available including pharmacophore ap-
proach with validation and a virtual screening; the MOE (Molecular Operating
Environment)2 has an automatic pharmacophore generation.
These programs have dierent algorithms for conformational exibility of the
ligands and molecular comparison. Regarding exibility issues, there are two
main approaches, either every possible conformation is calculated before or at
the same time the pharmacophore model is created. The molecular similarity
can be done in a superimposed way, (posing a challenge if the ligands are very
dierent and a similar origin point for comparison is dicult to determine) or,
using molecular eld descriptors.
2.1.2 SBDD - Structure based drug design
Structure based drug design approach uses the structure of the receptor to nd
molecules of interest and can be achieved in two steps:
1 - Identication or Prediction of the binding site.
2 - Docking and Scoring.
A concave region with several chemical functionalities is the ideal binding site
(Anderson, 2003). Docking a molecular combination requires a prediction using
the structure of the binding site and calculates their anity with ligands (Cheng
et al., 2012). Scoring a docking prediction is not an easy task as one protein
cannot be seen as a static entity; each protein can have a signicant number
of conformations, so scoring the ability of proteins to be docked by molecules
becomes a key and dicult step to achieve. This is the main reason why dierent
scoring functions exist, mainly based on force eld, empirical and knowledge-
based (Huang et al., 2010). Consensus scoring (using more than one type of
scoring in a combination) has been described as a more reliable way to nd the
1Discovery studio http://accelrys.com/products/collaborative-science/biovia-discovery-
studio/, last accessed 15 August 2016
2MOE http://www.chemcomp.com/MOE-Molecular_Operating_Environment.htm, last
accessed 15 August 2016
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correct ranking of lead compounds (Houston and Walkinshaw, 2013). There are
several software tools available for the binding site, docking and scoring prediction
(table 2.1).
Table 2.1: Binding site and Docking prediction softwares based on table from
(Joy et al., 2015)
Predicts Program/server Description
Binding site CASTp
Uses weighted Delaunay triangulation and the
alpha complex for shape measurements
Cavitator
Pocket prediction using a grid based geometric
analysis
ConCavity
Based on combining evolutionary sequence
and 3D structures
eFindingSite
Common ligand binding site prediction using
set of evolutionary related proteins
SiteComp
Binding site comparison based on molecular
interaction elds
Docking AutoDock Flexible side chains (genetic algorithm)
GOLD
Complete solution for docking small molecules
into protein binding sites
BP-Dock Flexible docking
Glide
Ligand exhaustive search and exible
side chains
idock Flexible ligand docking
SwissDock Rigid ligand with less than 10 rotational bonds
2.2 Molecular descriptors
In computational drug design, there is the need to represent compounds in such a
comprehensive way where it is possible to quantify their characteristics in a useful
manner. Molecular descriptors are numerical values which express properties of a
molecule and can be theoretical or a result of an experimental standardized test
(like dipole moment or polarizability). In theoretical descriptors, it is possible
to nd 5 classes (molecular descriptors 0D to 4D) each one more complex than
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the last. The rst class (0D) encompass descriptors directly obtained from the
chemical formula, like molecular weight, in the second class (1D) the structure
is represented in structural fragments (e.g. funcional groups) , the third class
(2D) have topological representations of the molecule, fourth class (3D) is a rigid
geometrical representation and the last class (4D) adds exibility to the 3D de-
scriptors giving the possibility to evaluate, for example, molecular interaction.
This values can bring insights between molecular structure and their associated
properties, as well as their biological activities. This makes them very useful
as input for the statistical methods in QSAR/QSPR and virtual screening stud-
ies (Karelson, 2000). Such as the blood-brain barrier penetration model (Martins
et al., 2012) and the prediction of standard enthalpy of formation of hydrocarbons
(Teixeira et al., 2013).
2.3 Supervised machine learning in QSAR
Supervised machine learning has a very important role in CADD (computer aided
drug design) since it is the way to refer to several methods of inferring results after
receiving a training data set with examples. This data set should contain the ob-
ject (it is usually a vector with a set of variables, e.g. molecular descriptors ) and
the expected output. The training data set is analysed and a learning algorithm
builds a model. Afterwards, the machine receives a test set, and using the model
constructed in the last phase, assigns each new data to a category, returning a
predicted class or value. The output of the supervised machine learning depends
on the characteristic to predict, either is in form of classes (classication), or in




2.3.1.1 Multiple Linear Regression
MLR(multiple linear regression) is the simplest regression model where a linear
relation between molecular descriptors and relevant biological activities is as-
sumed. The generic representation of this linear relation with specic weights for
each molecular descriptor can be represented as follows:
Y = β0 + β1X1 + β2X2 + ...+ βkXk
2.2.1.1
Where;
Y - Characteristic of interest to predict;
X0,...,k - Molecular descriptors;
β0,...,k - Weight of each molecular descriptor;
This linear approach can give us information of which molecule descriptors
have positive or negative eects in the characteristic of interest since it is possible
to see the weight of each descriptor. However, the descriptors chosen to be used
with this method should be non-linear from each other, since the weights can
be inuenced by linear related descriptors. The relation between the number
of molecules and the number of molecular descriptors should be around ve to
one (Topliss and Edwards, 1979). There are several papers using multiple linear
regression, in (Yang et al., 2016) was used to predict the anti-androgenic activity
of bisphenols, in (Min et al., 2016) aid in the prediction of inhibitors of hepatitis
B virus replication and (Grzonkowska et al., 2016) predicting the toxicity of ionic
liquids to Vibrio scheri gram-negative bacteria.
2.3.2 Non-linear models
2.3.2.1 Neural networks
Neural network is an algorithm based on a neuron where inputs are received and
transformed in outputs using a mathematical function. The idea behind a neural
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network is a series of nodes with dierent mathematical functions and weights,
which pass their outputs from one node layer to the next. In this type of approach,
several weak characteristics are used to obtain a good classication. The current
approaches are based in a perceptron, an algorithm created with the objective
to recognize patterns using only addition and subtraction functions (Rosenblatt,
1958). In supervised learning, the neural network is trained, and the weight
of each node is adjusted to achieve the best prediction possible (Teroth and
Gasteiger, 2001). Some examples of studies where neural networks algorithm was
applied are the aqueous solubility prediction of drugs (Huuskonen et al., 1998),
prediction of hepatic drug clearance in humans (Schneide et al., 1999) and QSAR
study of anti-HIV activity for a large group of HEPT (protein family) derivatives
(Jalali-Heravi, 2000).
2.3.2.2 Support vector machines
Support vector machines (SVM) proposed by (Vapnik, 1998) , can address classi-
cation and regression problems. In this supervised machine learning method the
training data is mapped in a very high dimension feature space or hyperplane,
which allows the representation of all instances. Given the classes or values in
each training instance and their location in the hyperplane, the algorithm creates
areas that will be used to determine predictions for the new data. The high-
dimension space is established using a Kernel function (linear, polynomial, radial
basis and sigmoid) (Yao et al., 2004). SVMs are broadly used, for example in
SAR/QSAR study of phenethylamines (Niu et al., 2007), prediction of mutagenic-
ity of compounds (Ferrari et al., 2009), QSAR models for predicting anti-HIV-1
activity of TIBO (molecule) derivatives (Darnag et al., 2010).
2.3.2.3 Ensemble methods
Ensemble methods are a combination of several supervised machine learning al-
gorithms, that give a nal result usually by weighted or unweighted voting of all
the results from individual models. This combination of methods are often much




Bootstrap aggregating (or bagging) is an ensemble method where a sub-
set/sample with the same number of instances from the original training set
with replacement is created, therefore some instances will be repeated and some
will not be present in the sample. For each bootstrap, a classier is created and
then aggregated to form the nal model. This method encompasses several small
models, therefore, can be a very robust tool reducing the over-tting problem.
Random forest algorithm (RF) develops decision trees using a dierent boot-
strap sample of the data apart from the past tree already constructed, the vari-
ables are arbitrarily selected at each node and chosen by their ability to divide the
sample. RF can be used for classication and regression, this forest of decision
trees, performs a classication depending on the class predicted by the majority
of trees, and the regression by the average of each tree prediction. Given its
construction is insusceptible to noisy variables and can operate with more vari-
ables than examples. Random forest is widely used from QSAR prediction of
compounds aquatic toxicity (Polishchuk et al., 2009), to prediction of standard
enthalpy of formation of hydrocarbons (Teixeira et al., 2013), or even QSAR
based model for discriminating EGFR inhibitors and non-inhibitors (Singh et al.,
2015).
Support vector machines and random forest provide good results despite a
large number of variables, making them the most used algorithms in QSAR and
virtual screening studies (Martins et al., 2012) (Teixeira et al., 2013). Given their
characteristics, this type of statistic methods needs to be performed in a vectorial
space environment.
2.4 Molecular similarity
Automated prediction (like QSAR) relies heavily in similarity tools, as such a
very small dierence between molecules can have critical consequences in their
chemical properties and activities. It is then important to use methods with a
good ability to dierentiate similar compounds (Martins et al., 2012). When
comparing small molecules, there are several problems that arise: rst of all
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the representation of this type of data is dicult, since molecules have very
specic structures and their size varies, becoming a true challenge to store them
in structured databases. Therefore when there is an attempt to dene a molecule
it is necessary to know that some information will be lost and that there are several
other ways to represent the same molecule. Even if representation strategies exist,
for example, SMILES (Simplied Molecular Input Line Entry System, where a
string represents the three-dimensional location of atoms and the type of bond
they share), there is always the challenge of choosing the right methodology
for comparison. Currently there are some methods for this comparison, however,
none seems to work universally (Teixeira and Falcao, 2013). All these methods can
be classied in three groups: i) structural descriptors (as in molecular descriptors
previously referenced), ii) molecular fragments (E.g. molecular ngerprints), iii)
graph theory.
2.4.1 Molecular Fingerprints
The ngerprints technique is a way of encoding the structure of a molecule and
is one of the most used techniques for molecular similarity. There are two main
types: a)hashed and b)circular.
Hashed ngerprints are a bit string representation of the molecule were "0"
represents the absence of a certain characteristic and "1" the presence of the same
characteristic. Depending on the type of ngerprint these characteristics can come
from a previous list (called keyed ngerprints) or can be a spatial representation
of each molecular fragment of a specic size, for example, of each N atoms and
N-1 bonds in each linear substructure.
Circular ngerprints (e.g. Morgan) evaluate the neighbours of each atom with
a dened radius. The radius parameter denes the distance between one atom
to their neighbour; when radius=1 the atoms evaluated are all the atoms bonded
to the atom in study, if the radius=2 it is possible to evaluate the atoms who
have a bond to an atom connected with the atom in study, as well as the atoms
with radius=1. Usually, the radius is set between 2 to 3 bonds. It is attributed
to each atom an unique identier that is updated according to the evaluations of
the neighbour atoms, after each iteration, there is a duplicate structural removal
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step. When the last evaluated neighbour reached the dened radius, all the
repeated identiers are removed again and then converted to a bit string.(Rogers
and Hahn, 2010)
To examine the similarity, these string bits have to be evaluated and a score
from zero to one is calculated. The most used metric is Tanimoto similarity or
Jaccard similarity coecient that is calculated using all presented characteristics
common (shared) to both molecules divided by the total number of characteristics











X - characteristics present in X's ngerprint.
Y - characteristics present in Y's ngerprint.






a - number of ones(or characteristics) in X's ngerprint.
b - number of ones(or characteristics) in Y's ngerprint.
c - number of ones(or characteristics) in both X and Y ngerprints.
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2.4.2 Non-contiguous Atom Matching Structural
Similarity
Non-contiguous Atom Matching Structural Similarity (NAMS) is a tool to com-
pare the structural similarity between small molecules(Teixeira and Falcao, 2013).
For a given pair of molecules, NAMS aims to nd a pair of atoms (one from each
molecule) that are the most equivalent between each other, representing each
molecule in a graph with atoms and their respective bonds. All the pair combi-
nations identied by NAMS are evaluated with the best match being selected for
the molecular comparison. However, one atom of a given molecule can only be
matched to one atom of a second molecule and vice-versa. The non-contiguous
part of this method relies on nding the best matching score, using all the pos-
sible combinations of atoms. Such matching process does not require contiguous
atoms or bond proles. After this step, NAMS calculates the Jaccard similarity
coecient (as mentioned in 2.3.1.2). In this situation, the variable "c" from Jac-
card formula is the common substructure in both molecules, where variables "a"
and "b" represent the self-similarity of each molecule. The main dierentiation
of NAMS is the ability to discriminate molecules by chirality or double bound
stereoisomerism that are rarely present in other similarity approaches.
NAMS also allows to choose between 5 scoring matrices that weight in dierent
ways the comparison of the replaced atoms:
Atom distance matrix 0: The most strict matrix, where each atom has only
100% similarity with itself and 0 from the remaining atoms.
Atom distance matrix 1: Almost as strict as matrix 0, but instead of 100%
similarity the value given is 90%.
Atom distance matrix 2: Similarity matrix based on literature.
Atom distance matrix 3: Empirical matrix constructed with known infor-
mation regarding the atoms.
Atom distance matrix 4: This matrix is the least strict matrix possible were
all the atoms as 0% similarity with all possible substitutions including itself,
which gives all the attention to the structure of the molecules.
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Fingerprints method and NAMS were already tested by (Teixeira and Falcao,
2013) using three datasets containing molecules with very similar characteristics
(therefore more dicult to dierentiate). In the end, only NAMS was able to
recognize the dierences and separate the molecules. Given this result, NAMS
was chosen as the main method for the comparison of molecules to the metric
branch of this dissertation, even though it has a higher computational cost.
2.4.3 Vector and metric spaces
In a vector space, one instance is represented as one vector, with several charac-
teristics and therefore dimensions. When one instance is represented in a metric
space with 2 dimensions, the distance between all the other occurrences is the
only characteristic that denes the instance, for example, dissimilarity between
instances. This dissimilarity cannot be represented directly in a 2-dimensional
metric space because the number of instances is the same as the number of dimen-
sions and this number is always greater or equal than 2, for example, a dataset
with 5 instances has 5 dimensions, but only 1 characteristic. To reduce to a
2-dimensional representation it is possible to do a principal component analy-
sis. The principal component analysis can study all the linear correlations be-
tween the data and transform them in non-linear components, these components
can be a combination of linear correlations, therefore the number of components
will be equal or less than the number of variables ( in this case the total of
instances). Each component is constructed in a non-linear correlation with the
previous established components and they are build up in a sequence from the
most explicative component to the less one. This statistic procedure returns a
summary of the information of the variance that is explained in each component,
so it is possible to verify if the datasets are properly expressed in two dimensions
- this procedure can be done in the R environment using prcomp function. To
organize these instances in a 2-dimensional graph, it is necessary to perform a
principal coordinate analysis or classic metric multidimensional scaling, which
arranges the instances in a plot with the minimum distortion possible - for which
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there is a function available in R denominated cmdscale1.
2.4.4 Inference in metric spaces
To infer in a metric space it is necessary to search the plotting points most similar
to the location where the inference is being performed since instances more close
to each other should be more related and aect the inference of the point to
be predicted. The proximity search between plotting points is calculated with a
function that satises the triangle inequality (where the sum of any two sides of
the triangle, must be greater or equal to the length of the remaining side) (Chavez
et al., 2001).
After this search, it is necessary to perform the interpolation of the data.
The geostatistical tool denominated kriging is a possible algorithm to execute
this process, interpolating the data in a geospatial space. This interpolation can
also be called Gaussian process regression since the interpolations are modelled
by a Gaussian curve. This geostatistical method aims to minimize the variance
of errors and to reduce the mean residual of error to zero (Teixeira and Falcao,
2014) and can use the variogram of the initial data to t the model - Ordinary
kriging is available in Gstat2 a R library. This technique was already used in
QSAR/QSPR approaches ((Fang et al., 2004), (Yin et al., 2007),(Teixeira and
Falcao, 2014)). Also, considered as a widely exible technique, it has been used to
perform interpolations in several dierent elds: soil quality (Smith et al., 1992),
atmospheric temperatures (Hudson and Wackernagel, 1994) and epidemiologic
map (Carrat and Valleron, 1991). When applied to a non-spatial problem it
is required to transform the data into spatial data, in order to represent the
problem in a metric space. To the best of our knowledge only one study used
structural similarity and a kriging algorithm (Teixeira and Falcao, 2014), all the
other researches used molecular descriptors sometimes previously selected.
1cmdscale https://stat.ethz.ch/R-manual/R-devel/library/stats/html/00Index.html, last
accessed 17 August 2016





The most common mutation that causes cystic brosis is F508del-CFTR which
originates a misfold and subsequently the retention in the endoplasmic reticulum.
CFTR is present throughout several cells in the body, more specically in the
membrane of epithelial tissues (eg: airways, intestine, pancreas, sweat ducts)
controlling the secretion of Cl− and uid, which when CFTR is defective increases
the viscosity (Wang and Li, 2014a).
CFTR is a ABC (ATP-binding cassette) protein. Most of these proteins
are active transporters ( were the transportation of a substrate is done against
the electrochemical gradient at some ATP expense). Usually, ATP binds to a
nucleotide-binding domain which can alter the conformation of transmembrane
domains and, therefore, enforce the substrate transport. CFTR, however, does
not function as an active transporter, since the ux of Cl− is done in favour of
the electrochemical gradient (Chiaw et al., 2011) .
In (Lewis et al., 2005) X-ray crystallography studies from F508del-CFTR
mutated protein suggests that the deletion of this phenylalanine does not block
the rst nucleotide-binding domain(NBD1) folding, but should aect domain-
domain assembly, and therefore causes a global conformation change resulting in
loss of channel function.
2.6 In silico screening
Several treatments have already been proposed for cystic brosis, however, most
of them failed to pass the drug development phases. Since this condition is
caused by mutations in CFTR (almost 2000 individual mutations identied so
far (Brodlie et al., 2015)), it is logical to consider the wild-type CFTR protein
as a treatment itself. Therefore it was developed a non-viral liposomal vector
to transport wild-type CFTR gene directly to the airway epithelial cells. The
introduction of this gene seems to work for several dierent mutations, however,
it only enhances the lung function and not the rest of epithelial cells aected
in the rest of the body (Alton et al., 2015). Another approach is the use of
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small molecules that interact with the defective CFTR, these molecules can be
separated into three categories:
Potentiators - molecules that enhance the channel function of proteins already
in the membrane;
Correctors - molecules with the aim to correct CFTR making it possible for
this protein to reach the membrane;
Read-through agents - which aects the ribosome to ensure that a mutation
in the CFTR gene does not result in a premature interruption of the protein
production resulting in a shortened non-functional CFTR.
Ivacaftor as already described before, is a potentiator that targets the Gly551Asp
CFTR mutation and can be applied to patients with at least one allele with this
mutation (Accurso et al., 2010).
Regarding the correctors, there are 2 molecules of interest: Lumacaftor (VX-
809) and VX-661. However, in this type of mutations the problem relies upon
the defective protein as it has diculties to achieve the membrane and even when
it reaches it, their gating function does not work properly. For this reason, the
correctors by themselves are not proposed as the solution, but a combination
of correctors and potentiators could help to treat this type of mutations(Cholon
et al., 2015) (Pilewski et al., 2015).
Ataluren (PTC124) is a read-through agent which targets non-sense muta-
tions that produce a premature stop signal, representing around 10% of cystic
brosis patients. This signal will stop ribosomal production of the protein before
achieving the right stop codon resulting in a loss of function. Ataluren enables
the ribosome to skip the premature stop signal originating a functional protein.
Some other eorts are worth mentioning: a study to use DHPs (used in a drug
to treat hypertension) as CFTR potentiators (Vietin et al., 2012) and a study






Data! Data! Data! he cried impatiently. I can't make bricks without clay!
Sherlock Holmes,The Adventure in the Copper Beaches
The main objective of this chapter is to describe each dataset, as well as their
origins and the pre-processing methods if applied, and also describe the selected
database.
Can we use datasets from Anoctamins potentiators & activators and CFTR
correctors in order to predict these capabilities in new molecules, and furthermore
proceed to a selection of molecules of interest? It is important to refer these two
datasets: i)Anoctamins potentiators and activators, ii)CFTR correctors, were
never tested in silico.
For the purpose of this project, the ZINC database was selected; ZINC is a
free database with a wide range of commercially available compounds organized
into subsets. To evaluate the nal results it was selected a published bioactivity
assay in CFTR.
3.1 Anoctamins potentiators and activators dataset
The molecules available in this dataset are the outputs of a similarity search
that uses a previous discovered anoctamin 1 activator. The lab design involved a
cell-based functional screening where mutant and non-mutant cells were used for
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high-throughput screening using uorescence to measure the I− inux. A protein
immunoblot was also performed to conrm the protein interaction.
3.1.1 Description
In this dataset, it is possible to encounter potentiators and activators. While
these molecules have the same function - reduction on [Ca2+] needed to activate
Cl− currents - there is a dierence in the amount of Ca2+ needed.
An activator strongly increases Cl− current at 0 [Ca2+], whereas a potentiator
is not active at a 0 [Ca2+] but reduces the EC50 - concentration where the eect
is half of the maximum - for Ca2+ dependent activation (Namkung et al., 2011).
There are 10 compounds with their respective mean value and SMILES. The
data is available for dierent compound concentration 0.1µM, 1µM, 10µM, 50µM
and in several cases, 100µM - all the considered concentrations of compound were
tested with 0.5µM [ATP] and without ATP. The concentration chosen for in silico
testing was 10 µM from the test without ATP to ensure that the results were not
aected by a purinergic receptor (ATP or ADP receptor).
3.2 Cystic brosis transmembrane conductance
regulator correctors dataset
This dataset includes several groups of molecules (secondary and tertiary group)
which originated from a similarity search using 4 primary CFTR correctors.
The CFTR correctors dataset comes from a western blot lab design. This tech-
nique also called protein immunoblot is used to nd specic proteins in samples,
and it considers the following three steps:
1 - Gel electrophoresis: Where the proteins are separated by a gradient of size
(if they are polypeptides ) or by type of structure. This gel has a variable
number of wells where to deposit the samples.
2 - Transfer to a membrane : Transfer of molecules to a membrane that has
anity to proteins and ensures afterward that all the proteins are locked in
place and that the membrane becomes not reactive to new bondings.
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dataset
3 - Marking proteins: Marking the target proteins with antibodies. An anti-
body can react to more than one protein but the location on the molecule
(that depends on the gel electrophoresis) and the marking make it possible
to discard false positives.
Once these steps are nished, it is possible to identify the marked proteins. This
detection can range from uorescent to colorimetric or even radioactive. To quan-
tify the amount of proteins in each band there are some tools that count the
number of pixels giving the ability to compare measurable results.
3.2.1 Description
The les available in this dataset contain the values obtained in the western blot
lab design for 4 primary molecules, 41 molecules from the secondary library and 64
from the tertiary library. One of those compounds was double counted resulting
in a total number of 108 compounds. The CFTR folder presents the results of
95 membranes for 108 molecules and for all of the controls: DMSO (Dimethyl
sulfoxide), F508del-cftr, Wild Type and C4a (CFTR corrector 4a). For in silico
testing, all the compounds were selected plus the C4a - a positive control known
to correct CFTR (gure 3.1).
Figure 3.1:




Given that each membrane has a dierent exposure time, a pre-processing of the
data was required to normalize the lab results used as inputs. To cover this, the






Vc - compound lab result
VWT - positive control value, for each membrane
VF508del - negative control value, for each membrane
When the MF508 lab results for one membrane are not available, the median
of all the MF508 data is used. The positive control represents the highest value
in that membrane and the negative value should be the lowest.
If the result from this formula is negative, meaning a compound enhance value
lower than the MF508 value, then the enhance value of that compound will be
set to zero.
In the gure 3.2 it is possible to visualize the dierence after the data was
processed. After the treatment the enhance values of the majority become zero
or close to zero; in this data, more than 50% of the molecules have an enhance
value equal or below the value of the CFTR 4F508del.
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Figure 3.2: Density representation of the enhance values in the initial data. A -
Before pre-processing. B - After pre processing.
3.3 ZINC - Database for virtual screening
The virtual screening step used in this project requires a compound database as
a dataset to infer the medical viability of several molecules. For this purpose, the
ZINC database was chosen.
As mentioned before, ZINC is a free database of commercially available com-
pounds that contains over 35 million molecules organized into subsets (by physical
properties and purchasable availability). It is possible to create small subsets for
personal use and there are several queries available: by name, structure, biologi-
cal activity, physical properties or even CAS number (unique identier assigned
by Chemical Abstracts Service to every chemical substance published from 1957
1) (Irwin et al., 2012).
This database is widely used in virtual screening approaches: structure-based
discovery to identify novel Smoothened (a Hedgehog group of proteins related
to cancer) ligands with dierent chemotypes in an eort to combat treatment
resistance (Lacroix et al., 2016); virtual screening approach to nd new leads
1CAS - A division of the American Chemical Society, CAS REGISTRY and CAS Registry
Number FAQs , website last accessed 15 August 2016
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against bovine brucellosis (Li et al., 2016); search for non-streroidal CYP17A1
inhibitors to treat prostate cancer (Bonomo et al., 2016); ligand-based drug design
for beta-1,3-glucan synthase inhibitors to conceive less toxic antifungal molecules
(Meetei et al., 2016).
It is important to mention the ability to download the entire database or
subsets in dierent formats, making it easy to run virtual screening locally. For
this project, the "all now" subset was chosen as it contains all the molecules
available in stock.
3.4 CFTR bioactivity assay
The assay selected is an already published bioactivity study from The Broad
Institute of MIT and Harvard 1. This assay uses halide-sensitive yellow uores-
cent protein (therefore, sensitive to Cl−) to determine the active concentration
of a drug in a cystic brosis bronchial epithelial cell line. In this assay, 1170
compounds were tested in the 4F508 mutation in Human bronchial epithelial
cells. Out of these 1170 compounds, 605 were considered active, 559 inactive
and 6 inconclusive. To facilitate the analysis these 6 inconclusive molecules were
removed from the set.









R1 is an open source programming language and environment which is designed to
perform an ample range of statistical methods. There is a large number of libraries
available that can aid in the construction of a program. This language was
chosen to do several statistical evaluations as well to create plots and graphical
representations of the data.
KNIME®2 Analytics Platform was the chosen software to support the
construction of the project workow. It is an open source data analytics platform
that allows the construction of workows using a graphical interface. In KNIME
there is a wide range of nodes available, including those with the ability to read
dierent input les, column sorting, machine learning, or even database con-
nections. Also, this program supports scripting in several coding languages like
Python3, R and Java, and allows the utilization of external tools in the computers
command line.
1R - https://www.r-project.org, last accessed 18 August 2016
2KNIME - https://www.knime.org/, last accessed 17 August 2016
3Python - https://www.python.org/, last accessed 17 August 2016
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RDKIT 1 is an Open-Source Cheminformatics Software that can be used to
calculate substructure searching, calculate dierent molecular ngerprints and
be used to lter functional groups. This software has several nodes available in
KNIME and can be used in Python and C++ coding languages.
4.2 Workow visualization
Figure 4.1: Workow main view screenshot.
1RDKIT - http://www.rdkit.org/, last accessed 17 August 2016
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The main view of the workow is available in image 4.1 where there are several
meta nodes (grey squares) which represent a group of nodes. Each part of this
workow will be explained in the next sections.
4.3 Workow input
In the project workow, the input information will be divided into three les:
i).smi le with SMILES and identication numbers of the dataset in use; ii).txt
le with the enhance values as well as their identication; iii).smi le from ZINC
with "all now" subset which has all the molecules available in stock.
4.4 Virtual screening candidates
Figure 4.2: Workow ZINC similarity representation.
The rst step of this workow is to select molecules from the zinc database that
are similar to the ones of the dataset in study ( 4.2 and B.1). With that objective
in mind, Morgan binary ngerprints will be calculated using RDKIT node present
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in KNIME. The parameters to be chosen are a radius of 2 atoms and a 1024 bits
length ngerprint (default values). To compare the ngerprints the similarity
metric selected will be the Tanimoto coecient, and the ZINC compounds picked
for further analysis will have 0.75 Tanimoto similarity or more, as they are more
accurately to predict. Otherwise, the whole process will be time-consuming and
imprecise.
4.5 Vector space mining
Figure 4.3: Representation of vector space workow branch.
In the vector space mining branch (gure 4.3 and B.4) both molecular data (i)the
dataset being studied, ii)previous selected molecules from ZINC) will have their
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descriptors calculated via an RDKIT node (molecular descriptors list available at
Appendix A). The descriptors of the initial molecules and their enhance values
will be used to train the random forest learner node.
Since random forest is insusceptible to noisy variables and can operate with
more variables than instances, a decision was made to keep all the molecular
descriptors without a previous selection.
The model created in the random forest learner node, as well as the molecular
descriptors of the ZINC molecules, will be used in the random forest node to
perform a regression analysis. Here the enhance values will be predicted using an
average of each prediction from individual trees.
4.6 Metric space mining
In the metric space mining part of this workow several steps were taken:
1 - The rst step of the metric space mining workow branch (gure 4.4 and
B.2) will be to calculate similarities between all the initial molecules. The
selected comparison method will be NAMS.





D - compound distance to other compound
s - compound similarity to other compound
3 - A principal component analysis will be then performed to evaluate the diver-
sity to be accounted into two dimensions using prcomp in R.
4 - A principal coordinate analysis or classic metric multidimensional scaling will




Figure 4.4: Representation of metric space workow branch.
5 - Perform interpolation using kriging (B.3). This prediction will be executed
in the R environment using ordinary kriging available in Gstat library.
In order to cmdscale perform a principal coordinate analysis, it needs the dis-
tances from each point to all the other points. This distance is the dissimilarity
or distance calculated using NAMS results in formula 4.6.1. Since an evaluation
of all the initial and new molecules would be time-consuming (due to the compu-
tational cost of NAMS), it will be necessary to construct a transformation matrix
that when multiplied by the distances between the initial molecules and the new
ones gives the coordinates for the new molecules. Thus, a similarity search will
be performed using NAMS to return the similarity values of each new molecule to
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the initial dataset and subsequently convert to distance as already described. The
development of the transformation matrix depends on the following principles:
A ∗ T = B
4.6.2
Where A is the distance matrix between all the initial molecules, T is the
transformation performed by the cmdscale function and B is the matrix with the
nal coordinates. Since the objective is to have the new molecules represented
in the same two-dimensional plan, the transformation matrix is required to cal-
culate the coordinates of the new compounds using their distances to the initial
molecules.
In order to obtain the T matrix the following formula was used:
T = A−1 ∗B
4.6.3
The T matrix will be calculated and then used to obtain the new coordinates
using the new distance matrix as in the formula 4.4.2. After these steps, all the
new and initial compounds can be represented in the same metric space and the
prediction can be performed.
4.7 Selection of molecules of interest
The selection of lead compounds will be done by choosing the most promising
molecules present in the upper right quadrant of the consensus plot. Only the
top 10 molecules from all the matrices (or the majority of matrices) selected for
that specic dataset will be identied for further analysis. Molecules that have
a prediction higher than the midpoint value in one method and a lower than
midpoint value on the other method may be considered as outliers. From this






The devil is in the details.
Anonymous
5.1 Anoctamins
In this dataset, the random forest algorithm can be less accurate as there are
only 10 molecules in the dataset, which is considered a low number to train this
statistical method. Also, a proper cross validation is dicult to achieve, because
each molecule contains a large amount of dierent information to be considered
in the model; for this reason, a validation was not performed.
Considering a tanimoto score of 0.75 or above, 71 molecules were selected
from ZINC database.
5.1.1 Variograms from metric space
The variogram plot is a good measurement to check if the data is spatially
correlated allowing the choice of an atom distance matrix for further analysis.
Considering this, the atom distance matrices that show some correlation are ma-
trix 0, matrix 1 (gure 5.1). As matrix 2, matrix 3 and matrix 4 do not show
enough correlation they were not chosen for further analysis.
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Figure 5.1: Variograms from anoctamins data with dierent matrices. A - matrix




Figure 5.2: A - Matrix 0 B - Matrix 1. Kriging image interpolations, the numbers
correspond to the initial molecules ids and the blue asterisks represent the loca-
tions of the new molecules from ZINC. The color palette expresses the predicted
values in that metric space where green is the lower prediction and white the
highest.
Giving the previously presented variograms the rest of the kriging prediction
was performed for matrices 0 and 1 with the respective kriging interpolation
plots (gures 5.2). The cumulative proportion of two components in the prin-
cipal component analysis for matrix 0 was 0.8084 and for matrix 1 was 0.8115,
demonstrating that two components are enough to substantially represent this
data. In the kriging images represented in the gure 5.2, it is possible to observe
the location of the hotspots as well as the new molecules location in the metric
space. Both images show a low number of molecules even before the selection
for further analysis. Also, it is possible to observe that between the clusters and
even between molecules from the same cluster there is a lot of metric space to
explore, because there were no molecules in ZINC for this locations. This can be
solved with a de novo approach.
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5.1.3 Consensus plot graph
Figure 5.3: Random forest vs kriging prediction values with matrix 0 (A) and




When using two methods for the same prediction it is possible that some molecules
will have a good prediction in one method and a bad one in the second method.
Therefore a consensus plot was developed to represent the dierences and the
concordances in the prediction values. This plot will show the predictions for
each molecule, where the X axis are enhance values predicted by kriging and the
Y axis are enhance values predicted by random forest.
The consensus plot graph (gure 5.3) clearly shows, that molecule 61 as the
best prediction values in both methods while molecule 62 and molecule 13 are
outliers to be considered. For the remaining molecules further analysis is needed,
using a supporting table where the coordinates for each molecule can be analysed.
5.2 CFTR
Using the CFTR dataset, 301 molecules were selected from ZINC to be evaluated
by random forest and kriging methods. The molecules selected had a tanimoto
similarity score greater or equal to 0.75.
5.2.1 Initial modelling
5.2.1.1 Variograms of the data
The methods used in the metric space depend on the correlation of the data, and
for this purpose, a variogram graph can indicate the reliability and feasibility of
such prediction for each individual matrix (gure 5.4 ). In this case, the validation
was performed using matrices that revealed some correlation. It was not possible
to perform this method with matrix 3 and 4 since the molecules were too similar
and several were categorized as equal.
5.2.1.2 Validation
When performing a 5-fold cross validation of the random forest method using
CFTR dataset (which have a standard deviation of 0.0387) the RMSE obtained
was 0.0382 and a explained variance of 0.0227. In the out of the bag validation,
the results were 0.0387 for RMSE and a negative explained variance of -0.0004.
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Figure 5.4: Variogram of CFTR data with matrix 0 (A) , matrix 1 (B) and matrix
2 (C).
These results show that the random forest model that receives the molecular
descriptors (the standard and widely used approach) is not able to explain the
data and therefore to predict values in new molecules.
The validation of the kriging algorithm was performed using a 5-fold cross
validation for the matrices 0 and 1. The RMSE for matrix 0 was 0.0413 and
for matrix 1 was 0.0403. As for the explained variance, the result for matrix 0
was -0.1419 and for matrix 1 was -0.0860. These results are aligned with the
validation results observed in the vector space branch, where random forest was
not able to predict the characteristics of new molecules accurately.
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5.3 Conrmatory model with raw data
Based on this validation, all the processes were analysed for errors where no is-
sue was found. Looking at the negative values of the explained variance in the
vector space method (already a widely tested process), a decision was made to
perform several cross validations using the random forest method; additionally,
changes to the initial input data were also performed. When all the instances
for each molecule and without the preprocessing treatment were tested, the ex-
plained variance obtained was 0.69. When the information about the membrane
and well of each molecule were removed, the explained variance dropped to nega-
tive values (-0.1053). These new tests indicate that the decisive characteristics for
the prediction was the molecule location (membrane and well) and the molecule
compound id but not the molecular descriptors, therefore the only plausible op-
tion is the mislabeling of our initial data. In order to be possible to perform the
molecular virtual screening is necessary to correct the mislabeling rst.
5.4 Identifying experimental mislabeling data
5.4.1 Mislabelling identication
Mislabelling of the data is dicult to correct since the experimental part was
performed by another party. Repeating the entire experiment was impossible
given time and money constraints, therefore the suitable solution was to create a
machine learning algorithm with the only information considered to be less prone
to have experimental errors. This machine learning algorithm iterates in all the
remaining data and one by one exchanging the compounds enhance values to try
to understand which changes aect the explained variance and subsequently the
prediction capability. This machine learning algorithm was iterating in molecular
similarity comparison and performed permutations until the explained variance
could not be enhanced any further. In this case, the data chosen as correct was
the primary molecules as well as the C4a corrector. Using the data from this 5




Given the problems with the initial dataset and to ascertain if the model created
with this transformed data can predict the activity of molecules from within the
dataset and the activity of new compounds foreign to the initial dataset. To test
the model created with this corrected dataset the already mentioned bioassay
available at Pubmed was used.
A classication using random forest was performed to validate the model and
predict the activity or inactivity of the compounds as tested by the study. A
confusion matrix was created with the results of this classication. A confusion
matrix is a 2x2 table were in the columns the variables are predicted positives
and predicted negatives and in the rows, the variables are real positives and
real negatives. Here, the values considered as real are the positive and negative
classications from the published assay. From the same classication, precision
and recall values were also obtained. The precision values can help realize the
proportion of true positives in all the predicted positives from the algorithm. This





TP - True positives - predicted positives that are real positives;
FP - False positives - predicted positives that are real negatives.
The recall value shows the rate of true positives in all the actual positives





TP - True positives - predicted positives that are real positives;
FN - False negatives - predicted negatives that are real positives.
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Given that the virtual screening selection relies on the true positives predicted,
both these values (precision and recall) are important to understand the rate of
true positives in all the predicted positives, as well as to realize from all the real
positives in the data which are predicted as positives.
The molecules available in the published dataset have a dierent range of
similarity when comparing to our initial dataset, as the values of similarity score
obtained with NAMS (using matrix 0) can range from 0.0269 to 0.9321. When
performing a prediction is necessary to have a degree of similarity, therefore in
order to achieve proper validation results, the top 10 and 20 similar molecules
were selected to be tested and the respective precision and recall values were
calculated. With the top 10 of molecules the precision obtained was 0.60 and
with the top 20 the precision obtained was 0.58. For both subsets, the recall
obtained was 0.12.
Regarding the metric branch, several dierent approaches were performed be-
cause the enhance value is calculated using dierent processes, making it dicult
to ascertain the validation directly. First, the values of enhance for the top 10and
20 similar molecules were predicted using kriging, then these values were cate-
gorized as positives and negatives using the average values of the ∆F508 CFTR
mutation as a threshold. With this categorization was possible to create another
confusion matrix and evaluate the already mentioned metrics. The results were
0.48 for the precision value and 0.46 for the recall value. Considering that this
classication was performed after the prediction there is the possibility of error
associated with the prediction and associated with the classication (primarily
the choice of the correct threshold), therefore a method for evaluation using only
NAMS was required.
For each primary molecule a plot with the predicted density of positives and
negatives throughout the similarity score was generated (graph 5.5). In these
density plots, is possible to observe that the actives have higher density values
than the negative compounds. The dierence sometimes is more visible than
others but suggests that similar compounds to the active ones are themselves
active as well.
Using the similarity calculated with NAMS (matrix zero) between the pri-
maries from our dataset and the molecules from the pubchem study, as well as
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Figure 5.5: Fraction of actives and inactives per similarity and per primary com-
pound.
their activity, a spline graph was created. A spline graph has a line which is
dened piece by piece using polynomial functions, in order to be approximated
to the real numbers and at the same time, construct a smooth line. This graph
was build considering the molecules with more than 0.3 similarity score, given
that a lower similarity score would not give pertinent information for this matter.
When analysing graph 5.6, the primary molecules 1 and 4 show an increasing
fraction of positives when advancing into more similar molecules. The primary
molecule 1 is the best of all primaries, thus it is very important that this molecule
has a good result, considering the positive fractions in increasing similarity. The
primary molecules 2 and 3 have similar results (as expected as they are very
similar). In both cases, the fraction of actives follows the increasing similarity
and starting from ∼ 0.5 similarity the fraction of actives decreased, mainly due
to several negative molecules closely similar to these two primaries.
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Figure 5.6: Fraction of actives per similarity and per primary compound consid-
ering only compounds with more than 0.3 similarity score
5.5 Final modelling
As previously mentioned 301 molecules were selected from ZINC to be subjected
to the virtual screening approach.
5.5.1 Vector Space
5.5.1.1 Cross-validation
The cross-validation of the corrected data was executed using a 5-fold and out-
of-the bag validation. This time the explained variance was 0.37 and 0.36 respec-
tively. The MSE was 0.004 with a standard deviation of 0.083. The mean error
of 100 iterations is available in a density graph 5.7. A confusion matrix was also
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Figure 5.7: Density representation of the mean error in 100 iterations of the
transformed data. A - 5-fold cross-validation. B - Out-of-the-bag cross-validation
created to compare with the results obtained in the reality check section. The
results of this confusion matrix were 0.61 for the precision value and 0.12 for the
recall value. These results are aligned with the ones observed in the previous
section: 0.60 for the precision value and 0.12 for the recall value.
5.5.2 Metric Space
The metric space was created using matrices 0, 1 and 2. Matrices 3 and 4 de-
scribed several molecules as equal given that some molecules are very close to
each other.
5.5.2.1 Variograms of the data
New variograms had to be calculated given the modications performed on the
data. As it is possible to observe in graph 5.8 all the three matrices show corre-
lation, thus the cross-validation will be performed on all of them.
54
5.5 Final modelling
Figure 5.8: Variogram of CFTR corrected data with matrix 0 (A) , matrix 1 (B)
and matrix 2 (C).
5.5.2.2 Cross-validation
The 5-fold cross-validation was performed for matrices 0, 1 and 2. The mean error
of 100 iterations is represented in graph 5.9. The RMSE was 0.071 for matrix 0,
0.72 for matrix 1 and 0.070 for matrix 2. The MSE value was 0,0051 , 0.0052 and
0.0049 respectively. Matrix 2 had the best explained variance with 0.29, followed
by matrix 0 with 0.27 and matrix 1 with 0.25.
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Figure 5.9: Density representation of mean error in the metric branch in 100
iterations. A - matrix 0. B - matrix 1. C - matrix 2.
5.5.2.3 Kriging - metric space prediction
The metric space prediction constructed with a principal coordinate analysis algo-
rithm is illustrated in graph 5.10, where it is possible to see the metric space and
the molecules positioning and distribution. It is also possible to see the dierence
between dierent areas concerning the amount of molecules.
The cumulative proportion of the two components ("X" and "Y" axis) range
from 0.79 in matrix 2 and 0.83 for matrix 0, therefore with this values is possible




Figure 5.10: Kriging prediction image with initial and new molecules. A - Matrix
0. B - Matrix 1. C - Matrix 2. The initial molecules are represented by their
id, and the new molecules are represented by blue asterisks. The color palette
chosen was terrain, where green represents a low value and white a high value.
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5.5.3 Consensus plot graph
The consensus plot graph (gures 5.11 ) represent the molecules predicted values
in two axes: The X axis represents the kriging method, while the Y axis represents
the random forest method. In the plots is possible to see the top molecules in
both techniques, and also the molecules with low prediction values across the two.
Together with the supporting table, these plots will be used to select the top
molecules and possible outliers in all the matrices. Even considering the overlap
of several molecules, some molecules can be considered to be selected: molecule
9 and 208 which are top molecules across the three matrices. Molecule 49 can
also be considered as it has a very low prediction from kriging and a considerable
value from the vector space (49 is overlapped by molecule 50 and in the consensus
plot in matrix 2). It is interesting to see a trend in the results of both spaces,
which are in accordance with our theoretical assumptions.
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Figure 5.11: Consensus plot with the predicted values from metric branch on the
x axis and the predicted values from the vector branch on the y axis. A - Matrix




Tell me and I forget, teach me and I may remember, involve me and I learn.
Xun Kuang
6.1 Anoctamins results
6.1.1 Most relevant descriptors in Anoctamins modelling
To evaluate the importance of each descriptor, every model created during the
cross-validation had the number of trees which use the attribute as split on level
0 and 1 (root and the next immediately split) summed up and then ordered from
the most used in this principal splits.
The most important variable seem to be SMR which calculates the molecular
refractivity assuming the washed structure, followed by Slogp the logarithm of the
coecient octanol/water for washed structures (in the correct protonation state).
The 3rd most important variable is LabuteASA (Labute's aproximate surface
area) gives the surface of each atom that is not inside or coincide with other atom
surface, giving the exposed surface of the molecule. The 4th and 5th most relevant
descriptors are the average and exact molecular weight. There are other variables
that can be also considered as relevant descriptors such as the TPSA (topological
polar surface area - which acts as a representation of the molecular permeability),
the number of hydrogen bond acceptors, the connectivity descriptors Chi1v and
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Chi2v 1, the number of heavy atoms and nally the total number of atoms.
With these descriptors in mind, it is safe to assume the importance of the sol-
ubility characteristics of the molecule as well as the connectivity between atoms
(especially the heavy) are very important characteristics to determine the poten-
tiation or activation of anoctamins.
6.1.2 Chosen matrices
The matrices that show some correlation in variograms 5.1 presented in the last
chapter were 0 and 1, the most strict matrices which can led to the assumption
that a substitution of one single atom can severely aect the molecule ability to
potentiate anoctamins action.
6.1.3 Selected molecules
As already referred in the methods section, it is important to select the best
combined predictions from both spaces, as well to choose some outliers of each
method (if there is some,) as a way to ascertain the error of this predictions when
compared to in vitro testing.
Based on the methods previously described there are 8 top molecules that
have the best results in both methodologies. These molecules are represented in
image 6.1. Two outliers were also selected and represented in gures 6.2 and 6.3.
1the atomic valence connectivity index and can be calculated by the sum of 1/sqrt(viji)
where i<j for all the bonds enclosed by heavy atoms i and j
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Figure 6.1: Final chosen molecules with good score from both methods.
Molecular representations retrieved from ZINC.
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Figure 6.2: Final chosen molecule with high score in random forest and low in
kriging.
Molecular representations retrieved from ZINC.
Figure 6.3: Final chosen molecule with high score in kriging and low in random
forest.




There are some evidences that support these results. It was performed a search
in dierent information repositories and some data was collected.
In Pubchem 1 ZINC09657902 can possibly target a calcium-dependent protein
kinase in Plasmodium Falciparum (malaria causing protozoan parasite) which can
be interesting because anoctamins are calcium-activated channel. ZINC06969746
can possibly target anoctamin 1 in Mus Musculus (commonly called as house rat).
ZINC08726656 was tested as potential chaperone treatment of Gaucher Disease.
6.2 CFTR results
6.2.1 Most relevant descriptors in CFTR modelling
The selection of important variables were performed in the same way as for the
anoctamins dataset. The most important descriptor seems to be SMR, followed
by LabuteASA. Then, two descriptors for the molecular weight (both average and
exact) seem to have almost the same importance. In 5th place, a connectivity
descriptor appears, Chi1v. There are other variables that can be also considered
as relevant descriptors such as Slogp, the number of atoms, TPSA, PSA (polar
surface area - dened as the sum of the surface of all the polar atoms), two
connectivity descriptors (Chi2v and Chi2n - simple molecular connectivity index
for path), and nally the number of heavy atoms.
These important variables are in accordance with the important character-
istics in the anoctamins data namely the solubility and the number of atoms
(especially heavy atoms).
6.2.2 Chosen matrices
Given the variograms presented in the last chapter, the top molecules were chosen
from the matrices that have a good variance/distance relation. These matrices
are matrix 0, matrix 1 and matrix 2 (gure 5.8). Given matrices 0 and 1 strictness
1last accessed in 15th of March of 2017
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it is possible to assume that the enhance value is correlated to strict congura-
tions changes and that a substitution of one single atom is really important for
the molecule ability to correct CFTR. Nevertheless, this does not diminish the
structure importance of the molecule but gives a remarkable penalization of atom
substitution.
6.2.3 Selected molecules
Figure 6.4: Final chosen molecules from virtual screening with top results for
both techniques in the three matrices.
Molecular representations retrieved from ZINC.
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Figure 6.5: Final chosen molecules from virtual screening with top results for
both techniques in two matrices.
Molecular representations retrieved from ZINC.
Analyzing the X and Y coordinates allowed the selection of molecules that
had top predicted values for both methods in three matrices (6 molecules, gure
6.4), and two matrices(4 molecules, gure 6.5). A selection of 6 outliers was
also performed with high random forest value and low kriging value or vice-versa
( gure 6.6 and 6.7 ). Also, for further analysis, 2 more molecules were selected
(gure 6.8). These molecules presented a top or good result for matrices 0 and
2 but a bellow midpoint prediction using matrix 1, these molecules should be
study to understand which matrix is more prone to accuracy in this dataset for
the continuation of this project.
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Figure 6.6: Final chosen molecules with high score in random forest and low in
kriging.
Molecular representations retrieved from ZINC.
Figure 6.7: Final chosen molecules with high score in kriging and low in random
forest.
Molecular representations retrieved from ZINC.
68
6.2 CFTR results
Figure 6.8: Two molecules considered outliers in matrix 1 but with good results
in matrices 0 and 2.
Molecular representations retrieved from ZINC.
6.2.4 Conrmatory analysis
As in the anoctamins dataset, further information about each of the selected
molecules was searched in the information repositories.
In Pubchem1, ZINC00257699, ZINC11077642 and ZINC00443340 can possibly
target anoctamin-1 in Mus Musculus (house rat). The molecule ZINC00257699
has a WIPO IPC ontology (World intellectual property organization International
Patent Classication) of "Drugs for disorders of the respiratory system".
According to Surechembl 2 ZINC04207443 is an inhibitor of histone deacety-
lase. This inhibition capability is interesting because there are reports showing
that reducing histone deacetylase 7 activity can restore function to misfolded
CFTR (Hutt et al., 2010).
1Pubchem https://pubchem.ncbi.nlm.nih.gov/, last accessed 13th of March of 2017





In this dissertation, a new methodology combining a widely used QSAR technique
and a new way to use machine learning in the molecular research environment to
predict therapeutic capabilities of several molecules was presented. Cystic brosis
is a disease were CFTR protein can have a large number of dierent mutations
that can be treated and/or controlled by correcting the CFTR malformations.
Another possible treatment course is to potentiate anoctamins action, as they
are present in several dierent cell lines and produces Cl− currents as CFTR.
Using an anoctamins potentiators and activators dataset as a starting point,
a query was performed to nd similar molecules in ZINC database. As a result
of this query 71 molecules were selected for further prediction. In order to in-
fer the therapeutic potentiator capability, two methods were applied. The rst
method is widely used in QSAR studies where each molecule is characterized
using molecular descriptors and a machine learning method is used (in this case
random forest) to learn from the initial dataset where the values to predict are
known and produce forecasts using the molecular descriptors of new molecules.
In this method, the molecular descriptors that seem to be more relevant to this
particular potentiation are related to the molecule's solubility, molecular weight,
and connectivity between atoms with a higher regard for heavy atoms. The sec-
ond method uses kriging as a data mining method; this method requires data
correlation and uses a topological representation of the data to infer values. In
order to predict the therapeutic potentiator capability kriging receives the simi-
larity between molecules calculated by NAMS program and represented them into
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a two dimensional-plot. In this method, the selection of the atom substitution
matrices from NAMS can give us some information about the molecules. In the
anoctamins dataset the matrices chosen was number 0 and 1, the two more strict
matrices available and therefore suggesting that a simple and similar change in
one atom is sucient to aect their ability to enhance the anoctamins function.
The outputs of both methods were then combined in a consensus plot to
select the most promising molecules for further testing. In total 8 top molecules
plus 2 outliers were selected based on the methods previously described. Once
the molecules were selected a search in biological repositories was performed to
review information about the molecules known targets or published bioassays.
Several interesting ndings arose in this search like a molecule that can target a
calcium channel protein like anoctamins, another that can target Anoctamin-1
or even a molecule that appears to have some interaction like a chaperone.
Regarding the CFTR correctors dataset the same methodology from
anoctamins could no be applied directly as the dataset had a mislabeling
problem. Knowing that it would not be possible to perform new laboratory
tests to the CFTR correctors, machine learning techniques were used to correct
the mislabeling error. To guaranty that this corrected dataset could be used to
infer characteristics of the molecules not present in the dataset, an evaluation of
the prediction was performed using a pubchem bioassay with F508del-CFTR (this
bioassay determines the activity or inactivity of molecules). After this correction,
it was possible to apply the same methodology from the anoctamins dataset. In
the CFTR dataset the matrices chosen were 0, 1 and 2, the two more strict matri-
ces, and one more equilibrated matrix, which allow us to infer that in this case,
very small dierences in the atoms can aect the molecules capacity to rescue
CFTR; but also that the matrix based on literature (matrix 2) have some eect
on this capability, suggesting that some molecular behaviour is explained with
this type of matrix and that these molecules are able to receive similar atoms and
maintain the relation of enhancing CFTR function.
Based on this, 301 molecules were selected from ZINC in order to be
evaluated by both methodologies. The important descriptors were also evaluated
and the important characteristics seem to be similar to the anoctamins dataset
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with solubility, weight, connectivity, and number of atoms as the most relevant
characteristics.
Similarly to the anoctamins potentiators dataset several molecules were se-
lected for further study: 10 top molecules with high predictions in both kriging
and random forest methods, 3 outliers with high prediction in molecular descrip-
tors and low in kriging and 3 other molecules with high prediction in kriging and
low from molecular descriptors. Also, 2 extra molecules were also selected given
that their predictions were good ou even top molecules in two matrices but below
midpoint result in another matrix - these should be further tested to understand
the dierences in predicting using dierent matrices.
A conrmatory analysis considering the literature available was also performed
showing a molecule that can possibly target Anoctamin-1 and another molecule
that is an inhibitor of histone deacetylase (which can possibly restore function to
misfolded CFTR).
In the CFTR dataset a 5-fold cross-validation was performed for each method:
in the vector space the explained variance was 0.37, a precision of 0.61 and a recall
of 0.12; in the metric branch the explained variance was 0.25 to 0.29 (depending
on the matrix used).
Given the cross-validation and conrmatory analysis results, the tested method-
ology seems to have some predictive power, however it is necessary to test the
molecules in the laboratory and improve the methodology with this results.
7.1 Future work
The immediate task is to test in vitro the selected molecules with a western
blot lab design to evaluate the methods used in this project. It is also possible
to perform another run in this workow using this new lab results to get more
precise predictions.
It is important to mention the several areas without molecules present in the
metric space. Although some areas were interesting (giving the kriging predic-
tions) they were not studied in this project because in the ZINC database was not
possible to nd molecules for those areas. One way to cover this issue is to design
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specic molecules in silico to perform computational tests, and subsequently, or-
der tailored molecules to test them. This specic molecular design can be done
either in pharmacophore based models or de novo approach.
It can also be interesting to create a similar double space approach with a dif-
ferent methodology in the vector space, maintaining this direct Kriging approach
since at the moment it is poorly explored in in-silico drug design methodology.
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Listing of molecular descriptor in
RDKIT
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A. LISTING OF MOLECULAR DESCRIPTOR IN RDKIT













































Figure B.1: Screenshot of the selection of ZINC molecules. Were it is possible to
see the ngerprint calculation and further selection. RDKit from molecule node
shows a yellow triangle given certain errors as duplication already mentioned
about ZINC database.
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Figure B.2: Screenshot of the metric branch were all the steps can be seen, since
NAMS similarity and coordinates calculation to Kriging prediction.
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Figure B.3: Kriging metanode were it is possible to see all the calculation and
graphs from this statistical method.
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Figure B.4: Vectorial branch screenshot with the calculation of RDKit descriptors




Figure B.5: Screenshot of reality check node were all the calculation using Ran-




C.1 Molecules SMILES from Anoctamins
Table C.1: SMILES of selected molecules from Anoctamins potentiators and
activators.
Project ID ZINC ID SMILES









High value in random forest and low prediction from kriging
62 ZINC08726656 Cc1ccc(cc1OC)C(=O)Nc1nc(cs1)c1ccccn1
High value in kriging and low prediction from random forest
13 ZINC00929111 COc1ccc(cc1)c1csc(n1)N(CCc1ccccc1)C(=O)c1ccc(cc1)OC
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C.2 Molecules SMILES from CFTR
Table C.2: SMILES of selected molecules from CFTR rescuers.
Project ID ZINC ID SMILES
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